Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?
Crossref DOI link: https://doi.org/10.1007/s40265-016-0578-z
Published Online: 2016-04-29
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Califano, Raffaele
Romanidou, Ourania
Mountzios, Giannis
Landi, Lorenza
Cappuzzo, Federico
Blackhall, Fiona
Text and Data Mining valid from 2016-04-29